arrow
P

P. Fournel

centre hospitalier universitaire de saint etienne
H指数:35
被引数:9,475

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial.

转移性子宫内膜癌患者中分子分型与总生存期的关联:UTOLA II期GINECO试验的辅助结果。

2025-11-210
PRE
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial

奥拉帕利维持治疗在铂类为基础化疗后的晚期/转移性子宫内膜癌中的应用:GINECO随机IIb期UTOLA试验

2025-08-260
OAAI
Exposure-response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO-NiQoLe study

尼拉帕利在复发性卵巢癌维持治疗中的暴露-反应关系:法国GINECO-NiQoLe研究的附加分析

2025-05-010
PRE
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study

真实世界中索托拉西布在KRAS G12C突变型转移性非小细胞肺癌患者中的有效性与耐受性:IFCT-2102 Lung KG12Ci研究

2025-03-010
OAAI
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)
2024-12-141
OAAI
LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer

LIBELULE研究:一项随机III期研究,旨在评估早期液体活检在可疑转移性肺癌患者中的临床相关性。

2024-12-012
OAAI
Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA

循环肿瘤DNA在转移性子宫内膜癌预后判断和监测中的验证:GINECO试验UTOLA II期随机研究的附加结果

2024-09-010
PRE
Spatial predictors of pathologic complete response to neoadjuvant chemotherapy using imaging mass cytometry in the IMMUcan TNBC cohort

使用成像质谱细胞术评估IMMUcan TNBC队列中对新辅助化疗达到病理完全缓解的空间预测因子

2024-09-010
PRE
Deep learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study

在IMMUcan研究中使用H & E图像和rna-seq对乳腺癌新辅助治疗的病理完全反应进行基于深度学习的预测

2023-10-010
OA
Olaparib vs placebo as maintenance therapy after platinumbased chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial
2023-10-014
OA
Pathologic complete response rate across triple negative breast cancer subtypes in the IMMUcan study
2023-04-040
PRE
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02)
2023-01-013
OAAI
Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study
2022-06-066
OAAI
Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network
2022-02-018
OAAI